SBI Life Insurance Company Ltd.
Banking · NSE
52-week range
₹1,691 – ₹2,129
From 52w high
-12.1%
RSI (14)
50.9
vs SMA 50 / 200
↓ 50 · ↓ 200
SBI Life Insurance (₹1,872) is India's second-largest private life insurer by new business premium, trading at a trailing PE of 75.9x and a forward PE of 54.1x. The stock is below its 50-DMA (₹1,902) and 200-DMA (₹1,921), down 8.2% over three months against a 12-month gain of 8.6%. ROE stands at 13.7% — below the 15% threshold in every year of the persistence window — and the quality score of 10 is the lowest among the six companies in its assigned sector group.
- ✓FCF was positive in 4 of the available years in the persistence window, indicating the insurance operations generate cash across most measured periods.
- ✓Forward PE of 54.1x represents a 29% compression from the trailing PE of 75.9x, implying the consensus earnings trajectory is materially upward from current reported levels.
- ✓The closest true peer comparison — HDFCLIFE (PE 69.7x, ROE 11.3%, quality score 20) — shows SBILIFE carrying a higher ROE (13.7% vs 11.3%) within the life insurance sub-sector, even as absolute quality scores are low for both.
- ✓Dividend yield of 0.14% is present, indicating a nominal capital return policy is in place, though at a negligible absolute level.
- ✗Quality score of 10 ranks last of 6 peers in the sector group, and ROE has not exceeded 15% in any year of the persistence window (roeYearsAbove15 = 0), with a consistency score of 48.
- ✗Trailing PE of 75.9x is the highest in the peer group and sits 9% above even the closest life-insurance comparable (HDFCLIFE at 69.7x), while 5-year earnings growth is -1.1% annualised — the valuation implies growth that has not yet materialised in historical numbers.
- ✗Price is below both the 50-DMA (₹1,902) and 200-DMA (₹1,921) with the stock down 8.2% over three months; the 52-week drawdown stands at 12.1%.
- ✗The sector peer group is predominantly commercial banks (AXISBANK, HDFCBANK, BAJFINANCE, BAJAJFINSV), making most quality and valuation comparisons structurally incompatible; the only true comparable is HDFCLIFE, limiting the analytical depth of sector benchmarking.
- ·Q4FY26 earnings were released around April 22–23, 2026; the company held an earnings call and subsequently made the audio recording available — no detail on whether results met, exceeded, or missed expectations is discernible from the available headlines.
- ·The most recent Life Insurance In Force data point was published May 10, 2026 (TradingView), suggesting ongoing disclosure of business volume metrics in the post-results period.
- ·All four recent news items carried neutral sentiment; no positive or negative events — regulatory actions, management changes, or analyst rating revisions — appeared in the sampled news window.
- ?Does the forward PE compression from 75.9x to 54.1x reflect a single expected step-up in earnings, or a multi-year compounding trajectory — and what embedded new business value (NBV) growth rate would be required to justify the current price?
- ?SBI Life's ROE of 13.7% has never crossed 15% in the persistence window while HDFCLIFE's ROE is 11.3% — does SBI Life's distribution advantage through the SBI bancassurance channel create a structural moat that ROE alone does not capture?
- ?The 5-year revenue figure of -82.2% is flagged as a probable reporting artifact — how does gross written premium and net premium income trend on a like-for-like basis over the same period, and what does that imply about top-line growth?
- ?With the stock below both its 50-DMA and 200-DMA and a 52-week drawdown of 12.1%, what operational or regulatory catalysts — such as IRDAI policy changes, interest rate shifts affecting investment yields, or persistency ratio improvements — have historically driven re-rating cycles for this stock?
PE
75.9
Forward PE
54.1
ROE
+13.7%
Profit margin
+2.2%
D/E
—
Dividend yield
+0.1%
Quality score
10/100
ROE 5y above 15%
0/5 yrs
FCF 5y positive
4/5 yrs
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.Analysis generated 10 May 2026.